Clinical results of randomized trials and ‘real-world’ data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research

References

• Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2016;mdw544. [Epub ahead of print].
   Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol. 2009;19:329–337.
   PubMed Web of Science ®Google Scholar
• Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437–443.
   PubMed Web of Science ®Google Scholar
• Shannon AM, Bouchier-Hayes DJ, Condron CM, et al. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 2003;29:297–307.
   PubMed Web of Science ®Google Scholar
• Unwith S, Zhao H, Hennah L, et al. The potential role of HIF on tumour progression and dissemination. Int J Cancer. 2015;136:2491–2503.
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368–4380.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593–4599.
   PubMed Web of Science ®Google Scholar
• Borgstrom P, Gold DP, Hillan KJ, et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 1999;19:4203–4214.
   PubMed Web of Science ®Google Scholar
• Marty M, Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer. 2008;44:912–920.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843–850.
   PubMed Web of Science ®Google Scholar
• Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19:851–856.
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30:117–124.
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–799.
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676.
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239–3247.
   PubMed Web of Science ®Google Scholar
• Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–1260.
   PubMed Web of Science ®Google Scholar
• Zielinski C, Lang I, Inbar M, et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17:1230–1239.
   PubMed Web of Science ®Google Scholar
• Gligorov J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1351–1360.
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29:4286–4293.
   PubMed Web of Science ®Google Scholar
• Vrdoljak E, Marschner N, Zielinski C, et al. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016;27:2046–2052.
   PubMed Web of Science ®Google Scholar
• Miles DW, Dieras V, Cortes J, et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol. 2013;24:2773–2780.
   PubMed Web of Science ®Google Scholar
• Rossari JR, Metzger-Filho O, Paesmans M, et al. Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence. J Oncol. 2012;2012:417673.
   PubMedGoogle Scholar
• Valachis A, Polyzos NP, Patsopoulos NA, et al. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2010;122:1–7.
   PubMed Web of Science ®Google Scholar
• Cuppone F, Bria E, Vaccaro V, et al. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials. J Exp Clin Cancer Res. 2011;30:54.
   PubMed Web of Science ®Google Scholar
• Lee JB, Woo OH, Park KH, et al. Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Invest New Drugs. 2011;29:182–188.
   PubMed Web of Science ®Google Scholar
• Wagner AD, Thomssen C, Haerting J, et al. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev. 2012;CD008941.
   PubMedGoogle Scholar
• Von Minckwitz G, Puglisi F, Cortes J, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1269–1278.
   PubMed Web of Science ®Google Scholar
• Brufsky A, Hoelzer K, Beck T, et al. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. Clin Breast Cancer. 2011;11:211–220.
   PubMed Web of Science ®Google Scholar
• Dieras V, Campone M, Yardley DA, et al. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Ann Oncol. 2015;26:1904–1910.
   PubMed Web of Science ®Google Scholar
• Lam SW, De Groot SM, Honkoop AH, et al. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial. Eur J Cancer. 2014;50:3077–3088.
   PubMed Web of Science ®Google Scholar
• Luck HJ, Lubbe K, Reinisch M, et al. Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. Breast Cancer Res Treat. 2015;149:141–149.
   PubMed Web of Science ®Google Scholar
• Mayer EL, Dhakil S, Patel T, et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010;21:2370–2376.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Bosserman LD, O’Shaughnessy JA, et al. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the sarah cannon research institute. Breast Cancer Res Treat. 2015;154:89–97.
   PubMed Web of Science ®Google Scholar
• Dieras V, Wildiers H, Jassem J, et al. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast. 2015;24:182–190.
   PubMed Web of Science ®Google Scholar
• Liu X, Liu X, Qiao T, et al. Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials. Onco Targets Ther. 2016;9:3771–3781.
   PubMed Web of Science ®Google Scholar
• Smith IE, Pierga JY, Biganzoli L, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol. 2011;22:595–602.
   PubMed Web of Science ®Google Scholar
• Smith I, Pierga JY, Biganzoli L, et al. Final overall survival results and effect of prolonged (>/= 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat. 2011;130:133–143.
   PubMed Web of Science ®Google Scholar
• Delaloge S, Perol D, Courtinard C, et al. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. Ann Oncol. 2016;27:1725–1732.
   PubMed Web of Science ®Google Scholar
• Mueller V, Dank M, De Ducla S, et al. Real-world effectiveness and safety of first-line bevacizumab (BEV) + paclitaxel (PAC) in >2000 patients (pts) with HER2-negative metastatic breast cancer (mBC). Ann Oncol. 2016;27: (suppl_6): 237P. ESMO Meeting Abstract.
   Google Scholar
• Roy V, Perez EA. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Res Treat. 2009;116:31–38.
   PubMed Web of Science ®Google Scholar
• Martin M, Loibl S, Von Minckwitz G, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol. 2015;33:1045–1052.
   PubMed Web of Science ®Google Scholar
• Haba J, Aguilar EA, Morales S, et al. ACE and CXCL10 as predictive biomarkers in the LEA study. Ann Oncol. 2016;27 (suppl_6): 135P. ESMO Meeting Abstract. .
   Google Scholar
• Dickler MN, Barry WT, Cirrincione CT, et al. Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016;34:2602–2609.
   PubMed Web of Science ®Google Scholar
• Carbognin L, Sperduti I, Ciccarese M, et al. Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: implications for post-progression and conditional survival. Breast. 2016;29:24–30.
   PubMed Web of Science ®Google Scholar
• Dufresne A, Pivot X, Tournigand C, et al. Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer. Int J Med Sci. 2008;5:100–105.
   PubMedGoogle Scholar
• Militello L, Carli P, Di Lauro V, et al. Bevacizumab as maintenance therapy (mBev) in metastatic breast cancer (MBC). ASCO Meet Abstr. 2013;31:e22149.
   Google Scholar
• Tredan O, Follana P, Moullet I, et al. A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study. Ann Oncol. 2016;27:1020–1029.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 2004;10:1706–1716.
   PubMed Web of Science ®Google Scholar
• Yang W, Klos K, Yang Y, et al. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer. 2002;94:2855–2861.
   PubMed Web of Science ®Google Scholar
• Pegram MD YC, Ku NC, et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER-2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat. 2004;88(suppl 1; abstr 30–39):S124.
   Google Scholar
• Martin M, Makhson A, Gligorov J, et al. Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist. 2012;17:469–475.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Badarinath S, Keaton MR, et al. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer. Clin Breast Cancer. 2014;14:161–168.
   PubMed Web of Science ®Google Scholar
• Lin NU, Seah DS, Gelman R, et al. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013;139:403–410.
   PubMed Web of Science ®Google Scholar
• Gianni L, Romieu GH, Lichinitser M, et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013;31:1719–1725.
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Mayer IA, O’Neill AM, et al. A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): A trial of the Eastern Cooperative Oncology Group (E1105). ASCO Meet Abstr. 2012;30:605.
   Google Scholar
• Drooger JC, Van Tinteren H, Sm DG, et al. A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: the HAT study (BOOG 2008-2003), a Dutch breast cancer research group trial. Cancer. 2016;122:2961–2970.
   PubMed Web of Science ®Google Scholar
• Hurvitz S. Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Cancer Res. 2009;69(24 Suppl):abstract nr 6094.
   Web of Science ®Google Scholar
• Rugo HS, Chien AJ, Franco SX, et al. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012;134:13–20.
   PubMed Web of Science ®Google Scholar
• Carbognin L, Furlanetto J, Vicentini C, et al. Neoadjuvant strategies for triple negative breast cancer: ‘state-of-the-art’ and future perspectives. Anticancer Agents Med Chem. 2015;15:15–25.
   PubMed Web of Science ®Google Scholar
• Golshan M, Garber JE, Gelman R, et al. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol. 2011;18:733–737.
   PubMed Web of Science ®Google Scholar
• Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol. 2013;24:2978–2984.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366:299–309.
   PubMed Web of Science ®Google Scholar
• Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13–21.
   PubMed Web of Science ®Google Scholar
• Nahleh ZA, Barlow WE, Hayes DF, et al. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat. 2016;158:485–495.
   PubMed Web of Science ®Google Scholar
• Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366:310–320.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Loibl S, Untch M, et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)dagger. Ann Oncol. 2014;25:2363–2372.
   PubMed Web of Science ®Google Scholar
• Earl HM, Hiller L, Dunn JA, et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:656–666.
   PubMed Web of Science ®Google Scholar
• Bertucci F, Fekih M, Autret A, et al. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2016;17:600–611.
   PubMed Web of Science ®Google Scholar
• Coudert B, Pierga JY, Mouret-Reynier MA, et al. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Lancet Oncol. 2014;15:1493–1502.
   PubMed Web of Science ®Google Scholar
• Steger GG, Greil R, Hubalek M, et al. Abstract P3-11-06: bevacizumab in combination with docetaxel+trastuzumab +/- non-pegylated liposomal doxorubicin: final results of ABCSG-32, a prospective, randomized phase II-study. Cancer Res. 2015;75:P3-11-06-P13-11-06.
   Web of Science ®Google Scholar
• Smith JW 2nd, Buyse ME, Rastogi P, et al. Epirubicin with cyclophosphamide followed by docetaxel with trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer or as adjuvant therapy for HER2-positive pathologic stage III breast cancer: a phase II trial of the NSABP foundation research group, FB-5. Clin Breast Cancer. 2016 Jul 28. [Epub ahead of print]..
   Google Scholar
• Pierga JY, Petit T, Delozier T, et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol. 2012;13:375–384.
   PubMed Web of Science ®Google Scholar
• Cao L, Yao GY, Liu MF, et al. Neoadjuvant bevacizumab plus chemotherapy versus chemotherapy alone to treat non-metastatic breast cancer: a meta-analysis of randomised controlled trials. Plos One. 2015;10:e0145442.
   PubMedGoogle Scholar
• Holmgren L, O’Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149–153.
   PubMed Web of Science ®Google Scholar
• Kumler I, Christiansen OG, Nielsen DL. A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev. 2014;40:960–973.
   PubMed Web of Science ®Google Scholar
• Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14:933–942.
   PubMed Web of Science ®Google Scholar
• Slamon DJ SS, Swain SM, Buyse M, et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. Cancer Res. 2013;73(24 suppl):abstract nr S1–03.
   Google Scholar
• Miller KOA. Dang CT. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern cooperative oncology group E5103. J Clin Oncol. 2014;32(5s):suppl; abstr 500.
   Google Scholar
• Cortes J, Calvo V, Ramirez-Merino N, et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol. 2012;23:1130–1137.
   PubMed Web of Science ®Google Scholar
• Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16:1037–1048.
   PubMed Web of Science ®Google Scholar
• Miles D, Cameron D, Bondarenko I, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer. 2017 Jan;70:146–155.
   PubMed Web of Science ®Google Scholar